Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2017 call → NOWe need to determine if the company is currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event at the end. The transcript is about Intra-Cellular Therapies, a biotech developing lumateperone. They are preparing an NDA for schizophrenia, expecting to submit mid-2018. They have a pre-NDA meeting later this month. They are also running clinical trials for bipolar depression, agitation in dementia, etc. They have cash of $464M and expect to spend $180-200M in 2018. They are building commercial infrastructure, hired a Head of Commercial Development. They are preparing for launch. The question: does management describe the company as currently living through a defined waiting period it is paying for out of its own pocket? That is, they are paying for something not yet earning, the wait is their main current work, and the far side is a specific near-dated event. Key points: They are spending on clinical trials, regulatory activities, manufacturing, pre-commercial activities. They are preparing for NDA submission and potential launch. The NDA submission is mid-2018, which is within a year. The launch would be after approval, but approval is not guaranteed. However, the question asks about a specific near-dated event that is already visible and depends on work already in motion. The NDA submission is a specific event they are working toward. They are paying for clinical trials and pre-commercial activities now, with no revenue yet. They have no approved products. So they are a pre-revenue biotech investing in development. Is that a "defined waiting period"? They are waiting for regulatory approval and launch. But the event they are working toward is the NDA submission, which is a milestone, not necessarily the earning event. The question says "the far side is a specific, near-dated, already-visible event" that ends the wait. The NDA submission is near-dated (mid-2018). But does that end the wait? After submission, they still wait for approval. The company is paying for clinical trials and pre-commercial activities now, with no revenue. That is typical for biotech. But the question asks if management describes it as a defined waiting period they are paying for out of their own pocket. They have cash and are spending it. They are not earning revenue. They are funding development.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.